Gene
EZH2
EZH2 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (1), Assay-provider ledger (46), Actionable biomarkers (2), and 8 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 more sections with rows · 1 section measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention EZH2. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 2 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 14 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 19 of 8,738 | 0.22% | not measured | |
| 2025 | 15 of 8,875 | 0.17% | not measured | |
| 2024 | 9 of 8,597 | 0.10% | not measured | |
| 2023 | 12 of 8,275 | 0.15% | 26 of 11,460 | 0.23% |
| 2022 | 7 of 8,285 | 0.08% | 37 of 13,598 | 0.27% |
| 2021 | 13 of 8,692 | 0.15% | 54 of 15,045 | 0.36% |
| 2020 | 6 of 7,640 | 0.08% | 43 of 14,459 | 0.30% |
| 2019 | 5 of 7,300 | 0.07% | 36 of 12,159 | 0.30% |
| 2018 | 7 of 6,927 | 0.10% | 36 of 11,854 | 0.30% |
| 2017 | 4 of 6,558 | 0.06% | 36 of 11,595 | 0.31% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (1)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| cobas EZH2 Mutation Test | EZH2 | Roche Molecular Systems, Inc. | Follicular Lymphoma Tumor | 2020-06-18 |
Assay-provider ledger (46)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network | Not a company | Analytical validation | 1 | February 18, 2025 |
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 3 | February 18, 2025 |
| BC Cancer Research Institute (Lab#2) | Not a company | Analytical validation | 1 | February 18, 2025 |
| Integrated DNA Technologies | Reagent supplier | Analytical validation | 1 | February 18, 2025 |
| Allogene | Pharma or other | No clinical or analytical validation recorded for this pair | 1 | February 01, 2025 |
Showing 5 of 46 assay-provider companies.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| EZH2 (Y641,A677) | Epz-005687 | response-associated | lymphoma | Cancer Genome Interpreter |
| EZH2 (Y641,A677) | Epz-6438 | response-associated | lymphoma | Cancer Genome Interpreter |
Trial mentions (112)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT02497404 | Trial eligibility (AACT) |
| NCT03303950 | Trial eligibility (AACT) |
| NCT06712173 | Trial eligibility (AACT) |
| NCT04217356 | Trial eligibility (AACT) |
Showing 5 of 112 trial mentions.
Target-disease associations (689)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anal Squamous Cell Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 689 associations.
Vendor sourcing (359)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). It is not observed in the gnomAD v2.1.1 da... | View ClinVar record SCV002011993.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1555T>C (p.S519P) alteration is located in exon 14 (coding exon 13) of the EZH2 gene. This alteration results from a T to C substitution at nucleotide ... | View ClinVar record SCV003589306.3 |
| Ascentage Pharma Group Inc. (United States) | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 in dose escalation or 0 to 2 in dose expansion * Has a life expectancy of ... | View trial NCT05415098 |
| Ascentage Pharma Group Inc. (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | EZH2 | View trial NCT05415098 |
| Assistance Publique – Hôpitaux de Paris | Trial sponsor | Biospecimen collected in a trialTrial biospecimen collection | No supporting text recorded; see the citation. | View trial NCT02823210 |
Showing 5 of 359 sourcing records.
Trial-cited literature (417)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study. | American journal of hematology | 2026 | 0 |
| <i>JAK3</i> <sup>A573V</sup> and <i>JAK3</i> <sup>M511I</sup> mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway. | Journal for immunotherapy of cancer | 2025 | 10 |
| Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. | EClinicalMedicine | 2025 | 5 |
| Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes. | JCO precision oncology | 2025 | 0 |
Showing 5 of 417 papers.
Protein variant mentions (17)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A636V | 1 | 2016 | PMID 27959900 |
| p.A678G | 1 | 2023 | PMID 37314226 |
| p.D185H | 2 | 2015 to 2022 | PMID 36275715, PMID 25741868 |
| p.E249K | 1 | 2015 | PMID 25741868 |
| p.E259Q | 1 | 2015 | PMID 25741868 |
Showing 5 of 17 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.A636V | RC-PTCL | Mature T- and NK-Cell Lymphomas; Connective, subcutaneous and other soft tissues; Liver and intrahepatic bile ducts; Unknown; Lymph nodes; Hematopoietic and reticuloendothelial systems | 1 | 58 | 1.72% | 0.30% to 9.14% |
| p.A636V | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Literature-extracted relations (86)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Gamma Aminobutyric Acid (GABA) | Chemical | associate |
Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation. | 2023 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial. | 2021 |
| Lymphoma, Follicular | Disease | associate |
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study. | 2025 |
| Lymphoma, B-Cell | Disease | associate |
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. | 2024 |
| Lymphoma, Follicular | Disease | associate |
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. | 2024 |
Showing 5 of 86 relation assertions.
Organizations publishing (453)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 36 | 2012 to 2024 |
| Dana-Farber Cancer Institute | Other | 27 | 2015 to 2024 |
| The University of Texas System | Academic | 21 | 2012 to 2026 |
| Harvard Medical School | Academic | 20 | 2009 to 2023 |
| Mayo Clinic | Hospital | 20 | 2013 to 2023 |
Showing 5 of 453 organizations.
Where EZH2 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
588 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects.